Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse

被引:83
|
作者
Grecu, Anca M. [1 ]
Dave, Dhaval M. [2 ,3 ,4 ]
Saffer, Henry [3 ]
机构
[1] Seton Hall Univ, Stillman Sch Business, Dept Econ & Legal Studies, Jubilee Hall 621, S Orange, NJ 07079 USA
[2] Bentley Univ, Dept Econ, 175 Forest St,AAC 195, Waltham, MA 02452 USA
[3] NBER, 5 Hanover Sq,Suite 1602, New York, NY 10004 USA
[4] Inst Lab Econ IZA, Bonn, Germany
基金
美国医疗保健研究与质量局;
关键词
Prescription drug abuse; opioids; Rx drugs; prescription drug monitoring programs; substance abuse treatment; H0; I1; K0; MEDICAL MARIJUANA LAWS; OPIOID PAIN RELIEVERS; NONMEDICAL USE; UNITED-STATES; COCAINE; OVERDOSE; PREVALENCE; ALCOHOL; DEATHS; TRENDS;
D O I
10.1002/pam.22098
中图分类号
F [经济];
学科分类号
02 ;
摘要
Despite the significant cost of prescription (Rx) drug abuse and calls from policymakers for effective interventions, there is limited research on the effects of policies intended to limit such abuse. This study estimates the effects of prescription drug monitoring (PDMP) programs, which constitute a key policy targeting access to non-medical use of Rx drugs. Based on objective indicators of abuse as measured by substance abuse treatment admissions and mortality related to Rx drugs, estimates do not suggest any substantial effects of instituting an operational PDMP. We find, however, that mandatory-access provisions, which raised PDMP utilization rates by actually requiring providers to query the PDMP prior to prescribing a controlled drug, are significantly associated with a reduction in Rx drug abuse. The effects are driven primarily by a reduction in opioid abuse, generally strongest among young adults (ages 18 to 24), and underscore important dynamics in the policy response. Robustness checks are consistent with a causal interpretation of these effects. We also assess potential spillovers of mandatory PDMPs on the use of other illicit drugs and find a complementary reduction in admissions related to cocaine and marijuana abuse.
引用
收藏
页码:181 / +
页数:34
相关论文
共 50 条
  • [1] Mandatory Use of Prescription Drug Monitoring Programs
    Haffajee, Rebecca L.
    Jena, Anupam B.
    Weiner, Scott G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (09): : 891 - 892
  • [2] Prescription drug monitoring programs, opioid abuse, and crime
    Dave, Dhaval
    Deza, Monica
    Horn, Brady
    SOUTHERN ECONOMIC JOURNAL, 2021, 87 (03) : 808 - 848
  • [3] The Effect of Mandatory-Access Prescription Drug Monitoring Programs on Foster Care Admissions
    Gihleb, Rania
    Giuntella, Osea
    Zhang, Ning
    JOURNAL OF HUMAN RESOURCES, 2022, 57 (01) : 217 - 240
  • [4] Prescription Drug Monitoring Programs and Other Interventions to Combat Prescription Opioid Abuse
    Chakravarthy, Bharath
    Shah, Shyam
    Lotfipour, Shahram
    WESTERN JOURNAL OF EMERGENCY MEDICINE, 2012, 13 (05) : 422 - 425
  • [5] Do prescription drug monitoring programs encourage prescription - or illicit - opioid abuse?
    Meadowcroft, Devon
    Whitacre, Brian
    SUBSTANCE ABUSE, 2021, 42 (01) : 65 - 75
  • [6] Prescription Drug Monitoring Programs Combating prescription drug misuse
    Gudoski, Anthony J.
    NURSE PRACTITIONER, 2015, 40 (11): : 28 - 33
  • [7] Prescription drug monitoring programs
    Miller, Michael M.
    Brown, Randall T.
    AMERICAN FAMILY PHYSICIAN, 2007, 75 (06) : 810 - 811
  • [8] The effect of cancer exemption in mandatory-access prescription drug monitoring programs among oncologists
    Graetz, Ilana
    Hu, Xin
    Ji, Xu
    Wetzel, Martha
    Yarbrough, Courtney R.
    JNCI CANCER SPECTRUM, 2023, 7 (02)
  • [9] PRESCRIPTION DRUG MONITORING PROGRAMS The Role of Asymmetric Information on Drug Availability and Abuse
    Meinhofer, Angelica
    AMERICAN JOURNAL OF HEALTH ECONOMICS, 2018, 4 (04) : 504 - 526
  • [10] Prescription Drug Monitoring Programs and Drug Overdoses
    不详
    PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 304 - 304